TY - JOUR T1 - cDNA Microarray Analysis of Gene Expression in Ovarian Cancer Cells After Treatment with Carboplatin and Paclitaxel JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 289 LP - 294 VL - 3 IS - 5 AU - L. RANDALL-WHITIS AU - DOUGLAS D. TAYLOR AU - Ç. GERÇEL-TAYLOR Y1 - 2006/09/01 UR - http://cgp.iiarjournals.org/content/3/5/289.abstract N2 - Background: Tumor resistance to chemotherapy results in ovarian cancer treatment failures. To understand the role of DNA damage, expression profiling was performed in ovarian cancer cells following suboptimal carboplatin (Carbo) and paclitaxel (Tax) treatments. Materials and Methods: Cell lines isolated from one patient were used. UL-3A was isolated at initial diagnosis, UL-3B after failure to cisplatin and Tax, and UL-3C at the final stages of the disease. Five clones isolated from UL-3A were also included. Sulforhodamine B assay was used to determine drug sensitivities. Gene expression was studied by DNA repair pathway specific microarray. Results: The cytotoxic phase was induced in all cells with Carbo and/or Tax treatments. Some cells recovered after individual drug treatments with the UL-3B cells surviving all modalities. Significant changes in the sensitivity of some surviving cells to chemotherapeutic agents were demonstrated. Carbo or Tax treatments resulted in significantly increased MDM2 and MSH6 and decreased 53BP1, EXT1, H2AFL and UNG expression. Combined Carbo and Tax treatment resulted in decreased ATR, CHEK1, PPM1D and PRKDC and increased RAD1, CDS1 and ATRX expression. Conclusion: Differential gene expression patterns were identified in cells that survived Carbo and Tax treatment that may be involved in ovarian cancer drug resistance. ER -